EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022

Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced a conference call scheduled for March 3, 2022, at 8:30 a.m. ET, to discuss its Q4 and full-year 2021 financial results and corporate developments. Interested participants can join by calling (877) 312-7507 domestically or (631) 813-4828 internationally, using conference ID 5058194. This presentation will also be available via live audio webcast on the company's website, with a replay accessible post-event. EyePoint is focused on therapeutics to treat serious eye disorders, leveraging its Durasert® technology.

Positive

• Company scheduled a conference call to discuss significant financial results.
• Focus on therapeutic advancements with proprietary Durasert® technology.

Negative

• None.

WATERTOWN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 3, 2022 to report its fourth quarter and full-year 2021 financial results and highlight recent corporate developments.

To access the live conference call, please dial (877) 312-7507 (domestic) or (631) 813-4828 (international) and reference conference ID 5058194. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert^® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert’s proven intravitreal drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ^® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Investors:

Christina Tartaglia
Stern IR
Direct: (212)-698-8700
christina.tartaglia@sternir.com

Media Contact

Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com

FAQ

When will EyePoint Pharmaceuticals release its 2021 financial results?

EyePoint Pharmaceuticals will announce its 2021 financial results during a conference call on March 3, 2022.

What is the ticker symbol for EyePoint Pharmaceuticals?

The ticker symbol for EyePoint Pharmaceuticals is EYPT.

How can I access the EyePoint Pharmaceuticals conference call?

You can access the conference call by dialing (877) 312-7507 for domestic calls or (631) 813-4828 for international calls, using conference ID 5058194.

What technology does EyePoint Pharmaceuticals use for drug delivery?

EyePoint Pharmaceuticals utilizes its proprietary Durasert® technology for sustained intraocular drug delivery.